DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT OFFICE ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION Denver Federal Center- Bldg. 20 6/12/2019, 6/13/2019, 6/17/2019, 6th Avenue and Kipling St. 6/18/2019, 6/21/2019 PO Box 25087 FEI NUMBER Denver, CO 80225 3004995630 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Mr. Joe D. Wise, Jr., Owner FIRM NAME STREET ADDRESS Joe Wise Pharmacy, Inc. DBA Wise Pharmacy 6179 S. Balsam Way Ste 150 CITY, STATE AND ZIP CODE TYPE OF ESTABLISHMENT INSPECTED Littleton, CO 80123 Producer of Sterile and Non-Sterile Drug Products THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE. DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED: OBSERVATION 1 The classified ISO 5 aseptic processing area was located within a non-classified room (segregated production area). Specifically, the ISO 5 certified (b) (4) used for aseptic filling of sterile drug products is located within a non-classified room which is not HEPA filter equipped. Additionally, pharmacy personnel move in and out of the unclassified Compounding Room, and conduct non-sterile compounding operations in the same room where the "(b) (4) " is located. The "(b) (4)" is opened and exposed to the non-classified environment during (b) (4) cleaning. On 6/13/2019, I observed the Sterile Pharmacist open the front panel on the "(b) (4)" and clean the interior of the (b) (4) with (b) (4) and sterile water. Furthermore, there is an approximate 3" crack on the front panel of the "(b) (4)", located in the upper right corner of the front panel, appearing to originate from a plastic screw-like piece that tightens the panel door (the front panel of the door (b) (4), allowing the operator to open it for cleaning). The Sterile Pharmacist stated the crack has been there since he started on 4/1/2019. (This is a Repeat Observation from the previous inspection in 2017) **OBSERVATION 2** Add Continuation Page EMPLOYEE(S) SIGNATURE EMPLOYEE(S) NAME AND TITLE (Print or Type) DATE ISSUED SEE OF THIS Jamie L. C. Dion, CSO 06/21/2019

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
THE PARTY OF THE CHAPTER		DATE(S) OF INSPECTION 6/12/2019, 6/13/2019 6/18/2019, 6/21/2019 FEI NUMBER	Water State Company of the Company o	
	ation: www.fda.gov/oc/industry	3004995630		
	F INDIVIDUAL TO WHOM REPORT IS ISSUED			
TO: Mr. Joe D	Wise, Jr., Owner			
FIRM NAME	1104,011,011.20	STREET ADDRESS		
Joe Wise Pharmacy, Inc. DBA Wise Pharmacy 6179 S. Balsam Way		6179 S. Balsam Way Ste 150		
CITY, STATE AND Z	SA POPULE CAR AND	TYPE OF ESTABLISHMENT INSPECTED		
Littleton, CO 80	Littleton, CO 80123 Producer of Sterile and Non-Sterile Drug		ducts	
Sinks or drains were present in the cleanroom where the ISO 5 classified aseptic processing area was located. Specifically, there is a sink and dishwasher located in the non-classified Compounding Room approximately 10' from where the ISO 5 certified (b) (4) is located. (This is a Repeat Observation from the previous inspection in 2017)				
OBSERVATI	ON 3			
You produced hazardous drugs without providing adequate containment and cleaning of work surfaces to prevent cross-contamination. Specifically, a deactivating agent is not used for cleaning non-sterile hoods in the non-classified Compounding Room. (b) (4) is used to clean (b) (4) hoods (Make: (b) (4)				
(b) (4) , Models: (b) (4) , IDs: (b) (4)) located in the non-classified Compounding				
Room and utilized for the weighing of hazardous and non-hazardous bulk drug substances. It is not possible to determine daily production sequence in these hoods; however, both hazardous and non-hazardous drugs may be weighed and mixed in each of the (b) (4) hoods during each day, including opioid and hormonal powders. OBSERVATION 4				
You used a non-pharmaceutical grade component in the formulation of a drug product.				
Specifically, your firm does not use pharmaceutical grade water to produce human drug products including: nasal solutions, suspensions, oral solutions, and ointments.				
Add Continuation Page				
	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or Type)	DATE ISSUED	
SEE REVERSE OF THIS PAGE	4.0.	Jamie L. C. Dion, CSO	06/21/2019	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT OFFICE ADDRESS AND PHONE NUMBER Denver Federal Center- Bldg. 20 6th Avenue and Kipling St. PO Box 25087 Denver, CO 80225	DATE(S) OF INSPECTION 6/12/2019, 6/13/2019, 6/18/2019, 6/21/2019 FEI NUMBER	6/17/2019,		
Industry Information: www.fda.gov/oc/industry	3004995630			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED				
TO: Mr. Joe D. Wise, Jr., Owner				
FIRM NAME	STREET ADDRESS			
Joe Wise Pharmacy, Inc. DBA Wise Pharmacy	6179 S. Balsam Way Ste 150			
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED			
Littleton, CO 80123	Producer of Sterile and Non-Sterile Drug Prod	ucts		
OBSERVATION 5 ISO 5 classified areas were not certified under dynamic conditions. Specifically, unidirectional airflow was not verified under operational conditions.				
Specifically, an in-situ air pattern analysis (smoke study) of the ISO 5 certified (b) (4) has not been conducted to demonstrate unidirectional airflow and sweeping action over and away from sterile drug products under dynamic conditions.				
OBSERVATION 6				
Environmental monitoring was not performed in your aseptic processing areas.				
Specifically, (b) (4) environmental (b) (4) (b) (4) touch plate samples collected from inside of the ISO 5 certified (b) (4) are incubated at uncontrolled room temperatures on the counter of the non-classified Compounding Room. The sterile pharmacist stated this is the process he has been following since he started on 4/1/2019.				
Further, the firm's certified (b) (4) incubator (Model: (b) (4), S/N: (b) (4) is not used to incubate environmental (b) (4) touch plate samples.				
Add Continuation Page				
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or Type)	DATE ISSUED		
SEE REVERSE OF THIS PAGE	Jamie L. C. Dion, CSO	06/21/2019		